Enbrel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The enbrel market size has grown strongly in recent years. It will grow from $16.82 billion in 2025 to $17.8 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of autoimmune diseases, strong clinical efficacy of tnf inhibitors, expansion of biologics adoption in rheumatology, established reimbursement coverage for biologics, physician familiarity with etanercept therapies.

The enbrel market size is expected to see strong growth in the next few years. It will grow to $22.05 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing biosimilar penetration pressure, increasing focus on cost-effective biologic alternatives, rising demand in emerging healthcare markets, expansion of specialty pharmacy distribution, continued innovation in biologic formulations. Major trends in the forecast period include increasing adoption of biosimilar competition, rising focus on patient-centric drug delivery formats, growing demand for long-term autoimmune therapies, expansion of combination therapy approaches, enhanced emphasis on cold-chain biologic distribution.

The rising prevalence of autoimmune conditions is expected to propel the growth of the Enbrel market in the coming years. Autoimmune conditions arise when the immune system incorrectly attacks the body’s healthy cells and tissues, causing inflammation and damage to various organs. The increasing occurrence of autoimmune conditions is linked to factors such as genetic predisposition, environmental triggers, and changes in lifestyle and immune system function. The growing prevalence of autoimmune conditions boosts the demand for treatments like Enbrel, which aids in managing inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. For example, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organization supporting people with arthritis and musculoskeletal conditions, by 2025, around 562,378 Australians are expected to be living with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the rising prevalence of autoimmune conditions is driving the expansion of the Enbrel market.

Major companies operating in the Enbrel market are securing drug approvals from regulatory authorities to strengthen their position in the industry. Drug approval is the process through which regulatory bodies assess and authorize a new drug for sale and use, confirming its safety, efficacy, and quality based on clinical trial evidence. For example, in October 2023, Amgen Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Enbrel for the treatment of children aged two and older with active juvenile psoriatic arthritis (JPsA). This approval emphasizes the distinct action of etanercept as a tumor necrosis factor blocker, demonstrated through extensive safety and efficacy studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. It also incorporates pharmacokinetic (PK) data supporting its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The recommended juvenile PsA (JPsA) dosage is based on body weight and administered via weekly subcutaneous injection.

In November 2023, Amazon Web Services Inc., a US-based cloud computing company, collaborated with Amgen Inc. to increase production capacity and deliver medications to patients more quickly worldwide. Through this collaboration, Amgen is utilizing AWS to create generative AI-based solutions aimed at speeding up the discovery, development, and manufacturing of medicines for patients with serious illnesses. Amgen Inc. is a US-based producer of Enbrel.

Major companies operating in the enbrel market are Amgen Inc.

North America was the largest region in the enbrel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enbrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enbrel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the enbrel market by increasing costs associated with imported biologic manufacturing inputs, cold-chain packaging materials, specialized syringes, and sterile filling components. North America and Europe are most affected due to reliance on cross-border biologics supply chains, while Asia-Pacific faces higher costs for biosimilar development and export activities. These tariffs contribute to elevated production and distribution expenses, influencing pricing strategies. However, they are also encouraging localized biologics manufacturing, regional fill-finish capacity expansion, and supply chain diversification to enhance long-term resilience.

The enbrel market research report is one of a series of new reports that provides enbrel market statistics, including enbrel industry global market size, regional shares, competitors with a enbrel market share, detailed enbrel market segments, market trends and opportunities, and any further data you may need to thrive in the enbrel industry. This enbrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enbrel, with the generic name etanercept, is a prescription medication used to manage various autoimmune disorders by suppressing the immune system. It is a biologic drug that functions by blocking tumor necrosis factor (TNF), a protein that triggers inflammation in conditions like rheumatoid arthritis and psoriasis.

The main products of Enbrel include injectable solutions, prefilled syringes, combination therapies, extended-release formulations, and biosimilars. Injectable solutions are liquid medications intended for administration via injection. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and other conditions.

The enbrel market consists of sales of monoclonal antibodies, cancer immunotherapy drugs and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.